Contact

Payer

Pharma

Provider

Formulary guidance and transparency from P&T to point of care

Radar On Market Access: Amazon Moves Further Into Health Care Data, Sharp Deal Shows

Posted by Peter Johnson on Sep 10, 2020

Health care industry insiders say that Amazon.com Inc.'s Aug. 27 deal to provide Halo fitness trackers to Sharp HealthCare indicates the retail and tech giant will make big bets on clinical and actuarial data analytics, AIS Health reported.

Sharp Chief Information and Innovation Officer Michael Reagin says that Amazon will provide the San Diego-based integrated plan and provider with about 500 of the wearable fitness trackers.

Read More

Topics: Market Access, Data & Analytics, Provider, Payer

Radar On Market Access: Some COVID Cost-Sharing Waivers Would Expire Soon

Posted by Leslie Small on Sep 8, 2020

Although federal relief legislation tied to the pandemic required health insurers to waive cost sharing for COVID-19 testing, not treatment, many plans opted to do both anyway. In fact, a recent analysis from the Kaiser Family Foundation (KFF) found that 80% of enrollees in the individual and fully insured group insurance markets were in plans that voluntarily waived out-of-pocket costs for COVID-19 at some point during the pandemic, AIS Health reported.

Yet according to the Peterson-KFF Health System Tracker analysis, published Aug. 20, 20% of individual and fully insured group plan enrollees are in plans where a cost-sharing waiver for COVID-19 treatment has already expired, and another 16% are in plans where the waiver is scheduled to expire by the end of September.

Read More

Topics: Industry Trends, Market Access, Data & Analytics, Payer

MMIT Reality Check on Breast Cancer HR+/HER2- (Sep 2020)

Posted by Matt Breese on Sep 4, 2020

According to our recent payer coverage analysis for hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Specialty, Market Access, Payer, Branding & Marketing

Radar On Market Access: Insurers Expand Flu Vaccination Outreach to Blunt COVID-19 Effects

Posted by Peter Johnson on Sep 3, 2020

Even as the COVID-19 crisis continues, public health officials are warning that an influenza pandemic might emerge this fall or winter. A double pandemic would kill even more people than COVID-19 on its own and strain the already overworked health care system. To prevent that deadly combination, plans have stepped up their usual flu-season member outreach programs, particularly for seniors, AIS Health reported.

In the Aug. 21 edition of its Morbidity and Mortality Weekly Report, the Centers for Disease Control and Prevention tied improved flu vaccination rates to reducing the strain that COVID-19 has put on the health care system.

Read More

Topics: Market Access, Data & Analytics, Provider, Payer

Radar On Market Access: USPS Delivery Slowdown Is Unlikely to Cause Major Rx Fill Disruption

Posted by Peter Johnson on Sep 1, 2020

The recent, sudden disruption of U.S. Postal Service (USPS) deliveries has caused concern about people receiving their medications later than they normally would. While news reports and statements by lawmakers indicate that many Americans have lost prescriptions in the mail or received them late, drug benefit and supply chain experts tell AIS Health the disruption to the most vulnerable patients served by specialty and mail order pharmacies should be minimal.

An Aug. 24 Axios-Ipsos poll shows that one in five Americans received medication through the mail during the preceding week. One in four of that group, or 5% of Americans overall, didn't receive their medication or got it late.

Read More

Topics: Market Access, Data & Analytics, Provider, Payer

MMIT Reality Check on Non-Small Cell Lung Cancer Systemic Therapy (Aug 2020)

Posted by Matt Breese on Aug 28, 2020

According to our recent payer coverage analysis for non-small cell lung cancer systemic therapy treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Specialty, Market Access, Payer, Branding & Marketing

Radar On Market Access: Large Employers Expect Cost Uncertainty, More Virtual Care in 2021

Posted by Leslie Small on Aug 25, 2020

While the COVID-19 pandemic has not caused employers to significantly alter their health care cost estimates for the coming year, it has unquestionably intensified their interest in embracing virtual care. Those are just a couple of the major findings from the Business Group on Health's 2021 Large Employers' Health Care Strategy and Plan Design Survey, AIS Health reported.

Notably, 80% of respondents said they believe virtual health will play a significant role in how care is delivered in the future, up considerably from 64% last year. Further, when asked about actions they were taking to ease the burdens of COVID-19 for employees, the largest share of respondents — 76% — said they "made changes to allow for better access to virtual care solutions."

Read More

Topics: Market Access, Data & Analytics, Provider, Payer

MMIT Reality Check on Ulcerative Colitis (Aug 2020)

Posted by Matt Breese on Aug 21, 2020

According to our recent payer coverage analysis for ulcerative colitis treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Specialty, Market Access, Payer, Branding & Marketing

Radar On Market Access: COVID-19 Pandemic Amps Up Interest in Home Care

Posted by Peter Johnson on Aug 20, 2020

As visits to hospitals and outpatient clinics have become sources of anxiety for patients worried about exposure to the novel coronavirus, plans and providers alike have begun to make major investments in home care, AIS Health reported.

Humana Inc., for example, recently announced a $100 million investment in home primary care startup Heal Inc. Heal CEO Nick Desai says his company will aid Humana's long-term strategy to reduce the cost of care and improve quality.

Read More

Topics: Market Access, Data & Analytics, Provider, Payer

MMIT Reality Check on Duchenne Muscular Dystrophy (Aug 2020)

Posted by Matt Breese on Aug 14, 2020

According to our recent payer coverage analysis for Duchenne muscular dystrophy treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Specialty, Market Access, Payer, Branding & Marketing